Tevogen Bio schedules its 2026 annual shareholder meeting for August 24, setting the stage for key governance votes
Executive summary: Tevogen Bio announced that its 2026 Annual Meeting of Stockholders will take place on August 24, 2026. The meeting provides shareholders with their regular opportunity to influence corporate governance and may precede the release of the company's proxy statement and any forthcoming business updates.
Who is involved: Tevogen Bio Holdings Inc. (Nasdaq: TVGN), its board of directors, and its shareholders.
Likely next: The company will file a proxy statement with the SEC ahead of the meeting, after which shareholders will vote on director elections, executive compensation and any other proposals.
The press release from GlobeNewswire confirms that Tevogen Bio Holdings Inc. will hold its 2026 Annual Meeting of Stockholders on Monday, August 24, 2026. The meeting follows standard regulatory practice for Nasdaq-listed companies, giving shareholders a formal venue to vote on board elections, executive compensation and other corporate matters. No additional details about agenda items were disclosed, so the announcement primarily serves as a procedural notice ahead of the typical proxy statement filing.
Timeline
- — Tevogen Bio Announces 2026 Annual Meeting of Stockholders (GlobeNewswire)
Analysis — what this means
Likely next events
- July-August 2026: Tevogen Bio to file its definitive proxy statement (Schedule 14A) with the SEC
- August 24, 2026: Annual Meeting of Stockholders held
- Post-meeting: disclosure of voting results and any approved corporate actions
Sectors affected
- Biotechnology
- Pharmaceuticals
Regulatory implications
- Must comply with Nasdaq Listing Rule 5605(c) requiring annual shareholder meetings
- SEC Schedule 14A filing required for proxy materials
- Shareholder vote on executive compensation subject to Dodd-Frank Say-on-Pay rules
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped